• Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.
  • Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.
  • Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.
     

MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ:EDAP, "EDAP"))) and Profound Medical Corp. (NASDAQ:PROF, TSX:PRN, "Profound"))), leading companies developing advanced minimally invasive and image-guided treatment ablative technologies for prostate cancer, including focal, subtotal, and whole-gland treatment approaches. These initiatives reflect Telix's commitment to advancing the integration of molecular imaging into the evolving prostate cancer treatment landscape to help inform clinical decision-making.

The collaborations will explore the investigational use of Telix's PSMA-PET imaging agents Gozellix® (kit for the preparation of gallium Ga 68 gozetotide) and Illuccix® (kit for the preparation of gallium Ga 68 gozetotide) with robotic high-intensity focused ultrasound (HIFU), and other image-guided therapies designed to treat localized prostate cancer, such as transurethral ultrasound ablation (TULSA).

Telix's intention is to work with select partners to explore how PSMA-PET imaging may support emerging therapy workflows, which aim to preserve healthy tissue and minimize the risk of side effects such as incontinence and impotence. Collaborative activities will focus on non-promotional scientific, educational, and research engagement.